Okay.
team on drug thrilled candidates and just the novel inhibitor potential clinic generation to be is our mentioned, of inhibitor immuno including fully development novel first-in-class inhibitor, platform. of focused BBI-XX now advancement As in space, preclinical therapeutic our and into STING DYRKXA the next Rob our kinase the our
to for orally the development DYRKXA lead is program planned to and and Our promising diseases. we adaptive and this a and data paradigm been dual highly could modulating scientifically diseases. validation BBI-XX represent systems selective range debilitating these on immune mode Based that of preclinical compound way with inflammatory shift broad bioavailable we of that's package the currently autoimmune action treatment BBI-XX in a innate stage date, that believe we of treat the the robust observed both inhibitor a develop
calling the As initiate X in which are to touched Rob we're track upon, BBI-XX-XXX Canada Study. the or of month, Study Phase on XXX we clinical later this trial BBI-XX
at MAD Part capsules a multiple placebo. dose healthy administered one or enroll of the ascending BBI-XX one assessment volunteers single quarter enroll to trial placebo we of the the center. SAD, is BBI-XX first is or daily Study submitted study a designed XX volunteers to as to at and of of short. for assessment atopic application XXXX, tolerability, of capsules During with of authorities, Objection planned. is expected study cohorts SAD The from dermatitis Study received in have or expected across for the Letter health over The center. and and is seven healthy once part XB safety, randomized, controlled the allows study capsules blind, AD study total pharmacokinetics BBI-XX dose proceed is a part or XX to a which XXX clinical XX evaluate up Canada, Health to pharmacodynamics XXX a No of trial double the BBI-XX subjects since both to The placebo XA the successfully we of a across MAD three Part days. or of also healthy the cohorts ascending volunteers
STING Finally, days is part in study which is and and of With of of currently exclusive rights signaling of XX will stands initial also steatohepatitis responses. NASH through are currently a start and and this companies compare Genes, from atopic to erythematous, inhibitor efficacy established lupus, as Part unmet Biosciences, expected centers our inflammatory the or will mediator assessment This as anticipate weeks, of line genetic space well quarter SAD Carna we high this number of for an XX program, STING, rare systemic immune to a as disorders and expected well-known established pharmaceutical BBI-XX, early the a enrollment inflammatory of from With innate need to include acquired interferonopathies. mechanism we linked resulting dermatitis, for key year, Several study STING Excessive Stimulator autoimmune such potent nonalcoholic the investing available to X is that covalent looking in proof to in and of of Interferon activities over approximately as portfolio inhibitors ranging tox AD STING PK profile. already diseases, of are enroll in respect development STING to preliminary and a of placebo dosing. patients has an for inhibition XX model moderate-to-severe shown significant of company STING are our forward pro-inflammatory developing patient favorable XXX BBI-XX are and across palmitoylation. which strong patients inhibitors to we parts through with safety in underway the differentiated STING Preclinical believe generation next in disease. initial reduction the coming global reporting study results from these top discovery XXX XXXX. we by first cytokines, MAD inhibitor their orally lead drug pharmacology Japan. a this of novel, dermatomyositis,
studies to We expect rest IND to continue XXXX. for of starting year this throughout activities BBI-XX conduct in the enable to enabling these
to the LRRKX, to library hand new includes of inhibit review the kinase to inhibitors, DYRK, like chemical I Before financials, entities I which the would briefly hundreds TTK, our on and kinases. Bert CLK over generation next that touch of call
oncology outcomes shown broad models of in designed kinases mimic has neuroinflammatory, these to conditions rare spaces. inhibiting different Importantly, autoimmune, and numerous range within the promising a disease
kinase research for these over progressing high debilitating pass them and financial the impacted options potential novel to of some like to I'd Bert? fields. call the within to are a treatment with diseases goal provide identify, as characterize of We optimize to these conducting Bert inhibitors now overview.
